Fourth, this study did not evaluate comparative effectiveness or cost-effectiveness relative to other treatment strategies, including switching to or initiating other glucose-lowering agents such as GIP/GLP-1 receptor agonists
The follow-up substance, semaglutide, has been developed into Ozempic as a diabetes treatment and Wegovy as an obesity treatment
When ketosis is added to semaglutide treatment, the theoretical and observed weight loss rate tends to increase because both approaches are simultaneously reducing caloric intake through appetite suppression, shifting metabolism toward fat oxidation, and improving insulin sensitivity
Brand-name semaglutide, sold as Wegovy or Ozempic, is FDA-approved as a finished product
The sterility is compromised after the first use, raising infection risk
some patients may be maintained at the 1.7 mg dose if needed